PRAX — Praxis Precision Medicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689548 ·
Last close
$280.78
Market Cap
$7.84B
52W High
$392.70
52W Low
$48.64
ADV30
400,110
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -96,904,000 | -83,720,000 | 1,390,102,000 | 474,761,000 | 49,058,000 |
| Mar 2026 | 0 | — | -105,860,000 | -92,561,000 | 1,460,202,000 | 536,333,000 | 50,241,000 |
| Dec 2025 | 0 | — | -97,044,000 | -88,911,000 | 937,907,000 | 357,329,000 | 59,771,000 |
| Sep 2025 | 0 | — | -78,359,000 | -73,934,000 | 396,388,000 | 149,527,000 | 52,883,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-282,210,000
Investing CF
$-604,359,000
Financing CF
$1,257,335,000
CapEx
$-62,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,232,569,000
Inventory
—
Receivables
—
ST Investments
$250,532,000
EBIT TTM
$-357,330,000
Pretax Income TTM
$-326,533,000
Interest Exp TTM
—
Analysts
18
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -326,198,000 | -303,268,000 | 937,907,000 | 59,771,000 | 878,136,000 | -249,068,000 |
| Dec 2024 | 8,553,000 | -200,165,000 | -182,819,000 | 483,110,000 | 37,660,000 | 445,450,000 | -131,757,000 |
| Dec 2023 | 2,447,000 | -126,373,000 | -123,277,000 | 87,948,000 | 18,279,000 | 69,669,000 | -111,136,000 |
| Dec 2022 | 0 | -214,986,000 | -214,029,000 | 115,128,000 | 39,022,000 | 76,106,000 | -185,043,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$770,000
NetIncome TTM
$-189,783,000
OpCashFlow TTM
$0
Assets (Latest)
$937,907,000
Forward EPS
$-9.29
Max Pain — expiry 2026-10-16
max pain strike: $340.00 · spot: $288.22 · call oi: 2,423 · put oi: 325
Expected Move to 2026-10-16:
±$36.00
(12.49%) —
implied range
$252.22 –
$324.22
· ATM straddle on $290.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.95B | $91.06 | — |
| SYRE | Spyre Therapeutics, Inc. | $7.56B | $85.69 | — |
| IONS | IONIS PHARMACEUTICALS INC | $7.40B | $44.50 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.79B | $57.43 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.89B | $19.77 | — |
News headlines (Yahoo Finance, 1h cache)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 20:01 · Yahoo
Praxis (PRAX) Q2 2026 Earnings Call Transcript
2026-08-13 16:29 · Yahoo
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?
2026-08-08 22:12 · Yahoo
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ...
2026-08-06 23:15 · Yahoo
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
2026-07-30 20:01 · Yahoo
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
2026-07-15 14:01 · Yahoo
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
2026-06-29 20:30 · Yahoo
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
2026-06-22 12:47 · Yahoo
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of
2026-06-22 12:00 · Yahoo
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
2026-06-15 03:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.